RxDoctor Payments Data

Fralan Gatte, APRN

Psychiatric/Mental Health · Lake Charles, LANPI 1912990516

Payments from drug & device makers

$4,304in general payments, 2019–2025

Across 70 payments — averaging $61.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$3K
  • Otsuka America Pharmaceutical, Inc.$364
  • Johnson & Johnson$228
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
  • Alkermes, Inc.$94
  • Teva Pharmaceuticals USA, Inc.$59
  • plus $68 from 3 others

What the payments were for

  • Speaking & faculty fees$1,98046%
  • Travel & lodging$87420%
  • Food & beverage$1,32631%
  • Education$1243%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,304 in reported general payments places this provider in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,401
Medicare patients
12
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate41$97,001
VraylarCariprazine Hcl12$17,874
Clozapine37$5,426
Divalproex Sodium ErDivalproex Sodium93$4,018
Oxcarbazepine36$2,456
Haloperidol Decanoate42$2,433
Quetiapine Fumarate114$1,304
Trazodone Hcl132$1,171
Divalproex Sodium14$989
Mirtazapine98$949
Buspirone Hcl68$922
Risperidone44$922
Sertraline Hcl106$866
Duloxetine Hcl97$800
Quetiapine Fumarate ErQuetiapine Fumarate13$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$228$97,00141 claims
AbbVieVraylar$38$17,87412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →